Anzeige
Mehr »
Dienstag, 17.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
839 Leser
Artikel bewerten:
(2)

Vaccine Adjuvants Market is expected to generate a revenue of USD 1308.41 Million by 2028, Globally, at 10.43% CAGR: Verified Market Research

The Vaccine Adjuvants Market is expanding as a result of numerous government initiatives to promote vaccinations, emerging chronic diseases, and the high prevalence of infectious and zoonotic diseases.

JERSEY CITY, N.J., Nov. 16, 2022 /PRNewswire/ -- Verified Market Research recently published a report, "Vaccine Adjuvants Market" By Product Type (Pathogen, Adjuvant Emulsion, Particulate), By Route of Administration (Oral, Intradermal, Intranasal), By Application (Infectious Diseases, Cancer), By Route of Application Category (Human Vaccine Adjuvants and Veterinary Vaccine Adjuvants), By Geographic Scope And Forecast.

Verified Market Research Logo

As per the deep research carried out by Verified Market Research, the global Vaccine Adjuvants Market size was valued at USD 625.23 Million in 2020 and is projected to reach USD 1308.41 Million by 2028, growing at a CAGR of 10.43% from 2021 to 2028.

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample/?rid=24286

Browse in-depth TOC on "Vaccine Adjuvants Market"

202 - Pages

126 - Tables

37 - Figures

Global Vaccine Adjuvants Market Overview

An immunological agent that aids in modifying the impact of other agents is the vaccine adjuvant. It is incorporated into the vaccine to enhance the immune response that guards against disease and offers enduring defence against the antigen. Adjuvants are added to vaccines to enhance the body's response to immunisation and decrease the number of vaccine doses administered to patients. The two adjuvants that are most frequently used are paraffin oil and aluminium hydroxide.

The high prevalence of infectious and zoonotic diseases and growing government vaccination initiatives are the main drivers of the global vaccine adjuvants market's expansion. The development of better and more durable vaccines for chronic diseases that are already prevalent and those that are on the rise is expected to drive the market. Additionally, the market is expanding due to the soaring demand for vaccine adjuvants intended to prevent a variety of chronic diseases with a high prevalence, including cancer, diabetes, arthritis, obesity, epilepsy, and others.

Key Players

The major players in the market are Invivogen, CSL Limited, Brenntag Biosector A/S, Avanti Polar Lipids, Inc., Agenus, Inc., MVP Laboratories, Inc., Novavax, Inc., OZ Biosciences, Seppic, and SPI Pharma, Inc.

Verified Market Research has segmented the Global Vaccine Adjuvants Market On the basis of Product Type, Route of Administration, Application, Route of Application Category, and Geography.

  • Vaccine Adjuvants Market, By Product Type
    • Pathogen
    • Adjuvant Emulsion
    • Particulate
    • Combination
    • Others
  • Vaccine Adjuvants Market, By Route of Administration
    • Oral
    • Intradermal
    • Intranasal
    • Intramuscular
    • Others
  • Vaccine Adjuvants Market, By Application
    • Infectious Diseases
    • Cancer
    • Others
  • Vaccine Adjuvants Market, By Route of Application Category
    • Human Vaccine Adjuvants
    • Veterinary Vaccine Adjuvants
  • Vaccine Adjuvants Market, By Geography
    • North America
      • U.S
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • U.K
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • Rest of Asia Pacific
    • ROW
      • Middle East & Africa
      • Latin America

Browse Related Reports:

Human Vaccine Adjuvants Market By Product Type (Pathogen Components, Adjuvant Emulsions), By Disease Type (Infectious Diseases, Non Infectious Diseases), By Route Of Administration (Oral, Subcutaneous, Intranasal, Intramuscular), By Geography, And Forecast

Vaccine Conjugate Market By Type (Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccines), By Target Disease (Pneumococcal, Influenza), By Pathogen Type (Bacterial Conjugate Vaccine, Viral Conjugate Vaccine), By Geography, And Forecast

CRM197 Market By Type (Research Grade CRM197 and cGMP Grade CRM197), By Application (Meningococcal Polysaccharide Conjugate Vaccine, Pneumococcal Conjugate Vaccine), By Geography, And Forecast

Vaccine Particulate Adjuvants Market By Product (Oral, Subcutaneous, Intramuscular, Others), By Application (Veterinary Vaccine, Human Vaccine), By Geography, And Forecast

10 Leading Vaccine Manufacturers offering immunity against the deadly viruses

Visualize Vaccine Adjuvants Market using Verified Market Intelligence -:

Verified Market Intelligence is our BI Enabled Platform for narrative storytelling in this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

About Us

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SME's offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defense, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact Us

Mr. Edwyne Fernandes
Verified Market Research
US: +1 (650)-781-4080
UK: +44 (753)-715-0008
APAC: +61 (488)-85-9400
US Toll Free: +1 (800)-782-1768
Email: sales@verifiedmarketresearch.com
Web: https://www.verifiedmarketresearch.com/
Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/1315349/Verified_Market_Research_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/vaccine-adjuvants-market-is-expected-to-generate-a-revenue-of-usd-1308-41-million-by-2028--globally-at-10-43-cagr-verified-market-research-301680111.html

© 2022 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.